About this trial

To improve the accuracy of risk prediction, screening and treatment outcome of cancer, we aim to establish a medical database that includes standardized and structured clinical diagnosis and treatment information, image features, pathological features, and multi-omics information and to develop a multi-modal data fusion-based technology system using artificial intelligence technology based on database.

Eligibility criteria

Qualifiers

Participants with the suspected of lung cancer/node, or stomach cancer/lesion, or colorectal cancer/leision

Participants that have signed informed consent.

Participants with detailed electronic medical records, image records, pathological records, multi-omics information, and other important clinical diagnostic information.

Healthy participants with no clinical diagnosis of lung cancer/node, or stomach cancer/lesion, or colorectal cancer/leision.

Disqualifiers

Participants with primary clinical and pathological data missing.

Participants lost to follow-up.

Participants with too poor medical image quality to perform segment and mark ROI accurately

Trial design

Treatments tested in this trial

  • No Intervention

Treatment groups

3,000 Participants
are divided into 3 treatment groups

Locations

1
Wuhan Union Hospital430000, WuhanHubei, China

Sponsors and collaborators

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Lead sponsor